Clinical trial
Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing…
NCT00115414 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00115414 |
|---|---|
| Title | Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC) |
| Official title | A Randomized, Double-Blind, Phase 2 Study Evaluating the Safety of Same Day Versus Next Day Administration of Pegfilgrastim With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) in Women With Breast Cancer |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Fever, Neutropenia |
| Intervention type | Drug |
| Interventions | pegfilgrastim, docetaxel, doxorubicin, cyclophosphamide |
| First posted | Jun 23, 2005 |
| Last update posted | Aug 1, 2008 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: